Study Information
Status: Active, Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
East Bay, San Mateo, Greater Sacramento Valley, Santa Rosa, San Francisco, Palo Alto/Santa Cruz, Modesto, Solano/Vallejo
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Lung Cancer (LUNG-MAP Sub-Study)